Loading...
XNYS
IQV
Market cap34bUSD
Jul 09, Last price  
208.97USD
1D
2.54%
1Q
24.88%
Jan 2017
174.78%
IPO
392.97%
Name

IQVIA Holdings Inc

Chart & Performance

D1W1MN
XNYS:IQV chart
P/E
25.64
P/S
2.14
EPS
8.15
Div Yield, %
Shrs. gr., 5y
-2.31%
Rev. gr., 5y
7.50%
Revenues
16.31b
+5.87%
3,924,020,0004,327,748,0004,865,513,0005,099,545,0005,460,000,0005,737,000,0006,815,000,0009,702,000,00010,412,000,00011,088,000,00011,359,000,00013,874,000,00014,410,000,00014,984,000,00015,405,000,00016,310,000,000
Net income
1.36b
-0.95%
160,596,000241,772,000177,546,000226,591,000356,383,000387,205,000115,000,0001,309,000,000259,000,000191,000,000279,000,000966,000,0001,091,000,0001,358,000,0001,373,000,0001,360,000,000
CFO
2.65b
-2.28%
378,160,000160,953,000335,701,000397,370,000431,754,000475,691,000860,000,000970,000,0001,254,000,0001,417,000,0001,959,000,0002,942,000,0002,260,000,0002,149,000,0002,716,000,0002,654,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

IQVIA Holdings Inc. is a global leader empowering the life sciences sector with advanced analytics, innovative technology solutions, and comprehensive clinical research services. Operating across the Americas, Europe, Africa, and the Asia-Pacific regions, its capabilities are organized into three main divisions. Within its Technology & Analytics Solutions segment, IQVIA delivers cloud-based applications alongside essential implementation services. It also specializes in real-world solutions, enabling clients to generate and disseminate crucial evidence that informs healthcare decisions and ultimately enhances patient outcomes. This segment extends its expertise to strategic and implementation consulting, encompassing advanced analytics and commercial process outsourcing. Furthermore, it furnishes comprehensive market performance data, tracking pharmaceutical sales, prescribing trends, treatment efficacy, and promotional activities at a granular level – from country-wide views down to regional, zip code, and individual prescriber insights, across diverse channels like retail, hospital, and mail order. The Research & Development Solutions segment offers a broad spectrum of support for clinical trials, from initial strategic planning and design to meticulous project management and clinical monitoring, including innovative virtual trial capabilities. Complementing these, it provides an extensive array of laboratory services, such as central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment focuses on engaging healthcare providers and patients, alongside offering scientific strategy and medical affairs support. IQVIA's client base spans pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. Additionally, the firm maintains a strategic alliance with HealthCore, Inc. Founded in 1982, the company was initially known as Quintiles IMS Holdings, Inc., before rebranding as IQVIA Holdings Inc. in November 2017. Its corporate headquarters are situated in Durham, North Carolina.
IPO date
May 09, 2013
Employees
87,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT